# NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

> **NCT03524898** · PHASE1,PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT03524898
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-02
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on this date in accordance with SAKK/CI.
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524898, "NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03524898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*